Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Acquire US Dengue Vaccine Developer Inviragen
May 9, 2013
- Kowa to Initiate Domestic PI Clinical Study of Anticancer Drug Codeveloped by NanoCarrier
May 9, 2013
- IFRS Implications to Be Seen in In-Licensed Products, M&A Processing
May 9, 2013
- Maruishi Licenses New Kappa Opioid Agonist from Cara Therapeutics
May 8, 2013
- BMKK to Increase Number of MRs to 1,000 by 2015
May 8, 2013
- Astellas: FDA Advisory Panel Did Not Back Approval of Tivozanib
May 8, 2013
- Shionogi Sponsors EMPATHY Study to Build New Evidence for Statins
May 8, 2013
- AnGes MG Eyes PIII Trial for Collategene in US, Europe by 2013-End
May 8, 2013
- Nichi-Iko Voluntarily Recalls Enalapril Maleate Tablets
May 7, 2013
- BI Japan’s Ethical Drug Sales Up 7.3% with Prazaxa Sales of 23.5 Billion Yen
May 7, 2013
- Fujifilm Kyowa Kirin Biologics Looking for Marketing Partners in Europe and US: Executive VP Kawaguchi
May 7, 2013
- Mochida Files NDA for PAH Treatment Treprostinil
May 7, 2013
- Daiichi Sankyo, Perosphere to Develop Anticoagulant Reversal Agent for Edoxaban
May 2, 2013
- Anticancer Agent Xtandi Receives Positive Opinion for Marketing Approval by EMA: Astellas
May 2, 2013
- Boehringer to Enter Oncology Market, Hire 100 MRs in Japan
May 2, 2013
- Boehringer Chief Says Japan Business Successful
May 2, 2013
- Astellas Vice President Miyokawa to Be Promoted to Representative Director
May 2, 2013
- Novartis Investigating Employee Involvement in Retracted Diovan Papers
May 1, 2013
- Torii Aims for Sales of 63 Billion Yen in FY2015, Expanding Allergen Field
May 1, 2013
- Torii to Launch Anti-HIV Drug Stribild Combination Tablets on May 14
May 1, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…